ArticleBioinformatics (Oxford, England)2019
A new computational drug repurposing method using established disease-drug pair knowledge.
Article in Bioinformatics (Oxford, England), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Leveraging neural network models for drug repurposing: a case study on cardiac hypertrophy.Scientific reports · 2026Article
- Enhancing drug repositioning: A multi-class ensemble model for drug-target interaction prediction with action type categorization.PloS one · 2025Article
- Explainable drug repurposing via path based knowledge graph completion.Scientific reports · 2024Article
- Drug Repurposing: A Leading Strategy for New Threats and Targets.ACS pharmacology & translational science · 2024Review
- A drug repurposing method based on inhibition effect on gene regulatory network.Computational and structural biotechnology journal · 2023Article
- KG-Predict: A knowledge graph computational framework for drug repurposing.Journal of biomedical informatics · 2022Article
- Computational drug repositioning using similarity constrained weight regularization matrix factorization: A case of COVID-19.Journal of cellular and molecular medicine · 2022Article
- A Study on Methodologies of Drug Repositioning Using Biomedical Big Data: A Focus on Diabetes Mellitus.Endocrinology and metabolism (Seoul, Korea) · 2022Article
- A global picture: therapeutic perspectives for COVID-19.Immunotherapy · 2022Review
- Drug Repositioning: Exploring New Indications for Existing Drug-Disease Relationships.Endocrinology and metabolism (Seoul, Korea) · 2022Article
- Evaluating the performance of drug-repurposing technologies.Drug discovery today · 2022Review
- Network analysis-based strategy to investigate the protective effect of cepharanthine on rat acute respiratory distress syndrome.Frontiers in pharmacology · 2022Article
- Biomarker-driven drug repurposing on biologically similar cancers with DNA-repair deficiencies.Frontiers in genetics · 2022Article
- Using predictive machine learning models for drug response simulation by calibrating patient-specific pathway signatures.NPJ systems biology and applications · 2021Article
- A Maximum Flow-Based Approach to Prioritize Drugs for Drug Repurposing of Chronic Diseases.Life (Basel, Switzerland) · 2021Article
- Article
- cando.py: Open Source Software for Predictive Bioanalytics of Large Scale Drug-Protein-Disease Data.Journal of chemical information and modeling · 2020Article
- Shotgun drug repurposing biotechnology to tackle epidemics and pandemics.Drug discovery today · 2020Article
- Shotgun drug repurposing biotechnology to tackle epidemics and pandemics.ChemRxiv : the preprint server for chemistry · 2020Article
- Drug targets for COVID-19 therapeutics: Ongoing global efforts.Journal of biosciences · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
motivationDrug repurposing is a potential alternative to the classical drug discovery pipeline. Repurposing involves finding novel indications for already approved drugs. In this work, we present a novel machine learning-based method for drug repurposing. This method explores the anti-similarity between drugs and a disease to uncover new uses for the drugs. More specifically, our proposed method takes into account three sources of information: (i) large-scale gene expression profiles corresponding to human cell lines treated with small molecules, (ii) gene expression profile of a human disease and (iii) the known relationship between Food and Drug Administration (FDA)-approved drugs and diseases. Using these data, our proposed method learns a similarity metric through a supervised machine learning-based algorithm such that a disease and its associated FDA-approved drugs have smaller distance than the other disease-drug pairs.
resultsWe validated our framework by showing that the proposed method incorporating distance metric learning technique can retrieve FDA-approved drugs for their approved indications. Once validated, we used our approach to identify a few strong candidates for repurposing. AVAILABILITY AND IMPLEMENTATION: The R scripts are available on demand from the authors. SUPPLEMENTARY INFORMATION: Supplementary data are available at Bioinformatics online.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.